Trials / Completed
CompletedNCT04185415
A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
A Participant-Blind, Investigator-Blind, Placebo-Controlled, Phase 1b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- UCB Biopharma SRL · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to assess the safety and tolerability of UCB0107 in study participants with Progressive Supranuclear Palsy (PSP).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | bepranemab | bepranemab will be administered in a predefined dosage. * Pharmaceutical Form: Solution for infusion * Route of Administration: Intravenous |
| DRUG | Placebo | * Pharmaceutical Form: Solution for infusion * Concentration: 0.9% w/v sodium chloride aqueous solution * Route of Administration: Intravenous |
Timeline
- Start date
- 2019-12-03
- Primary completion
- 2021-11-17
- Completion
- 2021-11-17
- First posted
- 2019-12-04
- Last updated
- 2023-12-01
Locations
13 sites across 4 countries: Belgium, Germany, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT04185415. Inclusion in this directory is not an endorsement.